|
|
|
|
Elutia Inc (NASDAQ: ELUT) |
|
Overall company Market Share Q1 2025 |
*Market share is calculated based on total revenue.
News about Elutia Inc Contracts |
September 5, 2024
Elutia Inc. Begins a New Era in Cardiac and Neurostimulation Treatment with EluPro BioEnvelope By Elutia Inc. (Nasdaq: ELUT) has announced a significant milestone in the field of cardiac and neurostimulation therapy with the first successful patient implant of EluPro, the world?s first antibiotic-eluting biologic envelope, sanctioned by the U.S. Food and Drug Administration (FDA). The procedure was conducted by Dr. John Catanzaro at East Carolina University Health Medical Center, marking a pivotal advancement in medical device technology aimed at reducing infection rates associated with cardiac pacemakers and neurostimulators. Elutia Inc. is a leading company in the development of drug-eluting biomatrix pr...
|
Publicly Traded Peers of Elutia Inc
Organogenesis Holdings Inc
Share Performance
+7.92%
This Year
|
Organogenesis Holdings Inc
Profile
Organogenesis Holdings Inc is a regenerative medicine company that specializes in the development and commercialization of advanced wound care and surgical biologic products. Their business model revolves around leveraging their expertise in tissue engineering and biotherapeutics to create innovative products aimed at treating various chronic and acute conditions. Through strategic partnerships, they distribute their products globally to healthcare professionals and patients in need, focusing on improving patient outcomes and quality of life.
More about Organogenesis Holdings Inc 's Market Share
|
Mymetics Corporation
Share Performance
-94.67%
One Year
|
Mymetics Corporation
Profile
Mymetics Corporation is a biotechnology company that focuses on the development of innovative vaccines and therapeutic products to address global health challenges. Their business model involves research, development, and commercialization of these products through collaborations and partnerships with pharmaceutical companies and government organizations.
More about Mymetics Corporation's Market Share
|
Integra Lifesciences Holdings Corp
Share Performance
-48.26%
This Year
|
Integra Lifesciences Holdings Corp
Profile
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
More about Integra Lifesciences Holdings Corp's Market Share
|
Mink Therapeutics Inc
Share Performance
+753.92%
One Year
|
Mink Therapeutics Inc
Profile
Mink Therapeutics Inc is a biotechnology company that focuses on developing mRNA therapeutics for treating genetic diseases. Their business model primarily revolves around utilizing messenger RNA (mRNA) to develop and deliver novel therapies that can address genetic disorders. By leveraging the potential of mRNA technology, Mink Therapeutics aims to offer innovative treatments that have the ability to fundamentally transform the field of genetic medicine.
More about Mink Therapeutics Inc 's Market Share
|
Adaptimmune Therapeutics Plc
Share Performance
-70.67%
One Year
|
Adaptimmune Therapeutics Plc
Profile
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
More about Adaptimmune Therapeutics Plc's Market Share
|
Alector Inc
Share Performance
-22.75%
This Year
|
Alector Inc
Profile
Alector Inc's business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.
More about Alector Inc 's Market Share
|
Dyadic International Inc
Share Performance
+4.85%
Over The Past 5 Days
|
Dyadic International Inc
Profile
Dyadic International Inc's business model revolves around developing and licensing proprietary microbial strains and technologies for use in the biopharmaceutical, biofuels, and industrial enzyme industries.
More about Dyadic International Inc's Market Share
|
Immunovant Inc
Share Performance
-41.88%
One Year
|
Immunovant Inc
Profile
Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.
More about Immunovant Inc 's Market Share
|
Novavax inc
Share Performance
-11.39%
30 Days
|
Novavax inc
Profile
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
More about Novavax inc 's Market Share
|
Valneva Se
Share Performance
-6.99%
Over The Past 5 Days
|
Valneva Se
Profile
Valneva is a biotech company that specializes in the development and commercialization of vaccines. Their business model revolves around research, development, manufacturing, and distribution of vaccines for various infectious diseases. Valneva aims to partner with pharmaceutical companies, governments, and international organizations to bring safe and effective vaccines to the market, addressing global health challenges.
More about Valneva Se's Market Share
|
Vir Biotechnology Inc
Share Performance
-41.79%
One Year
|
Vir Biotechnology Inc
Profile
Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.
More about Vir Biotechnology Inc 's Market Share
|
Vaxart Inc
Share Performance
-14.57%
This Year
|
Vaxart Inc
Profile
Vaxart Inc's business model involves the development of oral vaccines through their proprietary tablet vaccine delivery platform.
More about Vaxart Inc 's Market Share
|
Sources: Elutia Inc and all companies mentioned above in this report
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
